ARS Pharmaceuticals Inc (NASDAQ: SPRY) is 142.70% higher on its value in year-to-date trading and has touched a low of $2.55 and a high of $16.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SPRY stock was last observed hovering at around $12.63 in the last trading session, with the day’s gains setting it 0.67%.
Currently trading at $13.30, the stock is 3.56% and 15.51% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.21 million and changing 5.30% at the moment leaves the stock 53.64% off its SMA200. SPRY registered 79.73% gain for a year compared to 6-month gain of 47.78%.
The stock witnessed a 2.31% loss in the last 1 month and extending the period to 3 months gives it a 48.77%, and is 17.08% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.47% over the week and 6.67% over the month.
ARS Pharmaceuticals Inc (SPRY) has around 26 employees, a market worth around $1.29B and $0.50M in sales. Profit margin for the company is -8968.40%. Distance from 52-week low is 421.57% and -19.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.83%).
The EPS is expected to shrink by -12.72% this year.
ARS Pharmaceuticals Inc (SPRY) Top Institutional Holders
166.0 institutions hold shares in ARS Pharmaceuticals Inc (SPRY), with institutional investors hold 83.99% of the company’s shares. The shares outstanding are 96.41M, and float is at 48.66M with Short Float at 22.52%. Institutions hold 64.29% of the Float.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
The most recent transaction is an insider sale by Tanimoto Sarina, the company’s CHIEF MEDICAL OFFICER. SEC filings show that Tanimoto Sarina sold 100,000 shares of the company’s common stock on Sep 10 ’24 at a price of $11.50 per share for a total of $1.15 million. Following the sale, the insider now owns 1.4 million shares.
ARS Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 10 ’24 that Lowenthal Richard E (PRESIDENT AND CEO) sold a total of 100,000 shares of the company’s common stock. The trade occurred on Sep 10 ’24 and was made at $11.50 per share for $1.15 million. Following the transaction, the insider now directly holds 1.4 million shares of the SPRY stock.
Still, SEC filings show that on Sep 10 ’24, Lowenthal Richard E (Officer) Proposed Sale 300,000 shares at an average price of $11.36 for $3.41 million. The insider now directly holds shares of ARS Pharmaceuticals Inc (SPRY).
